Ginkgo Bioworks Holdings, Inc.
DNA
$7.54
-$0.27-3.46%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | 38.73% | 23.98% | 26.65% | 50.34% | 57.58% |
Total Depreciation and Amortization | -10.62% | -19.95% | 3.28% | 18.33% | 58.72% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | -48.88% | -33.44% | -42.71% | -65.79% | -73.07% |
Change in Net Operating Assets | -400.53% | -146.77% | 99.72% | 232.53% | 180.63% |
Cash from Operations | -8.15% | 2.11% | -2.70% | 8.89% | -17.17% |
Capital Expenditure | -53.28% | 17.02% | 42.34% | 58.80% | 21.94% |
Sale of Property, Plant, and Equipment | -85.37% | -30.14% | -40.58% | 7,734.48% | -- |
Cash Acquisitions | -- | -107.23% | -107.23% | -107.23% | -- |
Divestitures | -- | -- | -51.40% | -59.49% | 22.87% |
Other Investing Activities | 477.39% | 114.89% | 96.94% | 95.51% | 96.07% |
Cash from Investing | 22.87% | -2,139.43% | -87.84% | -44.40% | -19.73% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | 30.73% | 22.27% | 10.58% | 0.47% | -4.69% |
Issuance of Common Stock | -9.68% | -99.90% | -99.85% | -99.85% | -99.91% |
Repurchase of Common Stock | -- | 97.66% | 97.66% | 97.82% | 98.87% |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | 53.49% | 43.01% | 54.37% | 20.73% | -0.15% |
Cash from Financing | 45.93% | -102.28% | -102.12% | -103.32% | -103.37% |
Foreign Exchange rate Adjustments | 52.21% | -125.92% | -151.45% | -180.79% | -164.76% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -1.01% | -72.62% | -59.31% | -34.01% | -70.14% |